{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:41:10Z","timestamp":1793868070138,"version":"4.6.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Elevated lipoprotein(a) predicts high risk of cardiovascular disease among a modest proportion of healthy individuals, an issue that complicates screening guidelines.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine spline models, clinical thresholds, and percentiles of baseline lipoprotein(a) levels as 30-year determinants of cardiovascular risk.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This cohort study was conducted among female health professionals participating in the Women\u2019s Health Study, who were followed up prospectively from 1993 to 2023. Women without cardiovascular disease, cancer, and other major chronic illnesses had blood samples taken at baseline. All individuals with lipoprotein(a) measurements and\/or of European ancestry with genotype information for the\n LPA<\/jats:italic>\n rs3798220 variation were included. Data analyses were performed from January through April 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Continuously valued baseline lipoprotein(a), lipoprotein(a) clinical thresholds and percentiles, and\n LPA<\/jats:italic>\n rs3798220 genotypes known to predict lipoprotein(a) levels among individuals of European ancestry.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were incident major cardiovascular events, coronary heart disease, ischemic stroke, and cardiovascular death. Age- and multivariable-adjusted cause-specific Cox models were used to calculated hazard ratios for the cardiovascular outcomes. The hypothesis was formulated after collection of the data.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 27\u202f748 women with baseline lipoprotein(a) measurements and 23\u202f279 women of European ancestry with rs3798220 genotype information were included (median [IQR] age, 53 [49-60] years), among whom 3707 and 3165 major cardiovascular events, respectively, accrued during a median (IQR) follow-up period of 27.8 (22.8-29.4) years. Among women with lipoprotein(a) measurements, lipoprotein(a) levels above 30 mg\/dL or the 75th percentile (31 mg\/dL) were associated with increased 30-year risk of major cardiovascular events and coronary heart disease. Levels above 120 mg\/dL or the 99th percentile (131 mg\/dL) were associated with increased risk of ischemic stroke and cardiovascular death. Multivariable adjusted hazard ratios for levels above 120 mg\/dL vs below 10 mg\/dL or above the 99th percentile vs below the 50th percentile (11 mg\/dL) were 1.54 (95% CI, 1.24-1.92) and 1.74 (95% CI, 1.35-2.25) for major cardiovascular events, 1.80 (95% CI, 1.36-2.37) and 2.06 (95% CI, 1.49-2.84) for coronary heart disease, 1.41 (95% CI, 0.93-2.15) and 1.85 (95% CI, 1.17-2.93) for ischemic stroke, and 1.63 (95% CI, 1.16-2.28) and 1.86 (95% CI, 1.26-2.72) for cardiovascular death, respectively. Among women with genotype information, rs3798220 minor allele carriers had a higher risk of major cardiovascular events.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Per the results of this cohort study, very high lipoprotein(a) levels correlated with increased 30-year risk of cardiovascular disease among healthy women. Screening for elevated lipoprotein(a) in the general population may be warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.5043","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:31:05Z","timestamp":1767803465000},"page":"175","source":"Crossref","is-referenced-by-count":11,"title":["Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)"],"prefix":"10.1001","volume":"11","author":[{"given":"Ask Tybj\u00e6rg","family":"Nordestgaard","sequence":"first","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2013Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Chasman","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayaga","family":"Moorthy","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Kraaijenhof","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy R.","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Buring","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Division of Cardiovascular Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi250076r1","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"39","key":"hoi250076r2","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"10459","key":"hoi250076r3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease.","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"42","key":"hoi250076r4","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1093\/eurheartj\/ehad547","article-title":"Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life.","volume":"44","author":"Taageby Nielsen","year":"2023","journal-title":"Eur Heart J"},{"issue":"21","key":"hoi250076r5","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial.","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"20","key":"hoi250076r6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi250076r7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"hoi250076r8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial.","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"hoi250076r9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial.","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"hoi250076r10","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"34","key":"hoi250076r11","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi250076r12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"issue":"22","key":"hoi250076r13","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"hoi250076r14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease.","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"4","key":"hoi250076r15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"hoi250076r16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and White subjects: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"hoi250076r17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke.","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi250076r18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis.","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"issue":"24","key":"hoi250076r19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events.","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250076r20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population.","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"1","key":"hoi250076r21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank.","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"hoi250076r22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women.","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi250076r23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hoi250076r24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jacc.2025.02.032","article-title":"Prevalence of elevated lipoprotein(a) and its association with subclinical atherosclerosis in 2.9 million Chinese adults.","volume":"85","author":"Man","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi250076r25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi250076r26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"33","key":"hoi250076r27","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality.","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"hoi250076r28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women.","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi250076r29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"13","key":"hoi250076r30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250076r31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.294.1.56","article-title":"Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women\u2019s Health Study: a randomized controlled trial.","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"hoi250076r32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1373\/clinchem.2007.099366","article-title":"Rationale, design, and methodology of the Women\u2019s Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women.","volume":"54","author":"Ridker","year":"2008","journal-title":"Clin Chem"},{"issue":"6","key":"hoi250076r34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations.","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"24","key":"hoi250076r35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association.","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"14","key":"hoi250076r36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes.","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250076r37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts.","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"26","key":"hoi250076r38","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi250076r39","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","article-title":"Genome-wide association study of peripheral artery disease in the Million Veteran Program.","volume":"25","author":"Klarin","year":"2019","journal-title":"Nat Med"},{"issue":"21","key":"hoi250076r40","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease.","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hoi250076r41","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging lp(a)-lowering therapies.","volume":"85","author":"Barkas","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250076r42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi250076r43","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"12","key":"hoi250076r44","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"issue":"4","key":"hoi250076r45","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application.","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"7","key":"hoi250076r46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research.","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"hoi250076r47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk.","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"hoi250076r48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study.","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"hoi250076r33","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harell","year":"2001"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2843429\/jamacardiology_nordestgaard_2026_oi_250076_1770405030.58747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:00:17Z","timestamp":1770825617000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2843429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.5043","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}